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Cytochrome P450The bioactivation of pro-toxicants is the biological process through which some chemicals are metabo-
lized into reactive metabolites. Therefore, in vitro toxicological evaluation should ideally be conducted
in cell systems retaining adequate metabolic competency and relevant to the route of exposure. The
respiratory tract is the primary route of exposure to inhaled pro-toxicants and lung-derived BEAS-2B cell
line has been considered as a potentially suitable model for in vitro toxicology testing. However, its met-
abolic activity has not been characterized.
We performed a gene expression analysis for 41 metabolism-related genes and compared the proﬁle
with liver- and lung-derived cell lines (HepaRG, HepG2 and A549). To conﬁrm that mRNA expression
was associated with the corresponding enzyme activity, we used a series of metabolic substrates of CYPs
(CYP1A1/1B1, CYP1A2, CYP2A6/2A13 and CYP2E1) known to bioactivate inhaled pro-toxicants. CYP activ-
ities were compared between BEAS-2B, HepaRG, HepG2, and A549 cells and published literature on pri-
mary bronchial epithelium cells (HBEC).
We found that in contrast to HBEC, BEAS-2B and A549 have limited CYP activity which was in agree-
ment with their CYP gene expression proﬁle. Control cell lines such as HepG2 and HepaRG were metabol-
ically active for the tested CYPs. We recommend that similar strategies can be used to select suitable cell
systems in the context of pro-toxicant assessment.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license. 1. Introduction
The need for in vitro cell systems as alternatives to animal mod-
els for toxicological testing is increasing in response to new regu-
lations, such as the EU 7th Amendment Directive (European
Commission, 2003), and to ethical considerations like the 3Rs prin-
ciple (Schechtman, 2002). Due to their relative homogeneity and
ability to be maintained in culture indeﬁnitely, established cell
lines have been one of the preferred cell systems employed in
the development and validation of in vitro toxicology assays. Most
continuous cell lines, however, have been derived from malignant
or transformed tissue and fail to replicate the physiology and mor-
phology of normal cells. Historically, hepatic cell lines have been
thoroughly characterized, as they are the prime systems used for
drug metabolism and toxicity testing in pre-clinical development(Guguen-Guillouzo and Guillouzo, 2010; Brandon et al., 2003).
For instance, the hepatoma cell line HepG2 lacks normal metabolic
activity and has been engineered to express hepatic cytochrome
P450 (CYP) enzymes (CYP3A4, CYP2E1) to study in vitro drug hep-
atotoxicity caused by compounds such as paracetamol (Yoshitomi
et al., 2001). CYP3A4 and CYP2E1 catalyze the transformation of
paracetamol into a highly reactive metabolite responsible for the
tissue speciﬁc toxicity of the drug. This process of metabolic trans-
formation of a chemical (pro-toxicant) into a toxic species is de-
ﬁned as bioactivation and is a key element in many toxicity
studies. In contrast, many other cell lines used in toxicology, and
in particular non-hepatic cells, have not been extensively charac-
terized for their metabolic competency. The deﬁciencies in the
metabolic capabilities of cell lines could lead to inaccurate evalua-
tion of test compounds (Kirkland et al., 2007). This is the case for
benzo[a]pyrene (B[a]P), a well-known tobacco smoke chemical
that is ultimately metabolized to a diol-epoxide carcinogen by
the inducible lung CYPs, CYP1A1/1B1. The formation of B[a]P
DNA adducts has been reported in vitro using lung carcinoma-de-
rived A549 cells (Feldman et al., 1978) but the role of CYP1A1/
1B1 in the formation of such adducts in A549 was not demon-
strated at the time. In 2000, Hukkanen and colleagues reported
the expression and inducibility of CYP1A1/1B1 in the A549 cell line
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CYP1A1 was not required in A549 for the oxidation of B[a]P to its
reactive form and that this reaction could be catalyzed by AKR1B10
(Quinn et al., 2008). However CYP1A1 activity was reported the
same year by EROD assay after A549 induction (Billet et al.,
2008). In contrast, in a comparison between CYP1A1/1B1 activity
in A549 and HBECS Newland et al. showed that the CYP1A1 activity
in A549 was limited when compared to a culture of human pri-
mary lung epithelial cells when incubated with a luminogenic
probe substrate. Thus the mechanism of adduct formation in
A549 can potentially follow multiple metabolic routes different
than what would be expected in a normal lung epithelium. CYP2B6
activity has also been reported in A549 together with mRNA
expression of CYP2D6, 2E1, 3A5, and CYP3A7, the latest is not ex-
pected to be present in normal adult tissue. Other key lung epithe-
lium CYPs such as CYP2A6, CYP2A13, and CYP2F1 involved in the
bioactivation of toxicants such as nitrosamines were not detected
in this cell line. This example highlights the importance of charac-
terizing the metabolic enzyme proﬁle in cell lines used for toxico-
logical evaluation, with the possibility to restrict such study to
enzymes relevant to the metabolic pathway of speciﬁc toxicants.
However, to date, there is no standard approach to metabolic char-
acterization. Where some researchers focus on gene expression
only (Jennen et al., 2010) others may combine gene expression
with enzyme activity (Westerink and Schoonen, 2007).
The aim of our investigation was to describe an experimental
strategy combining quantitative real time PCR (qPCR) and func-
tional enzymatic assays applied to the lung-derived BEAS-2B cell
line. Initially, we proﬁled the gene expression of a panel of oxida-
tive and conjugative metabolism-related genes involved in xenobi-
otics metabolism, more speciﬁcally related to the toxicity of
cigarette smoke to human lung (Hecht, 2006). Next, we used a ser-
ies of metabolic substrates and inhibitors to test the enzyme activ-
ity of key CYP enzymes. The selection was made taking into
account the relevance of the target organ and the nature of the test
article. The human lung-derived BEAS-2B cell line was ﬁrst de-
scribed in 1988, when normal bronchial epithelial cells obtained
from autopsy of non-cancerous individuals were isolated, then in-
fected with a replication-defective 12-SV40/adenovirus hybrid and
cloned to create an immortalized phenotype (Reddel et al., 1988).
The non-cancerous phenotype of BEAS-2B cells is an advantage
in the investigation of carcinogenic processes such as DNA damage
and cell transformation (Sun et al., 2011). Therefore, BEAS-2B cells
have been considered as a relevant cell line for in vitro toxicology
testing in the ﬁeld of pollutants, tobacco products and nanomate-
rials (Persoz et al., 2012; Veljkovic et al., 2011; Haniu et al., 2011).
Although, several studies have employed BEAS-2B cells to evaluate
the effect of some pro-toxicants such as B[a]P and 4-(N-methylnit-
rosamino)-1-(3-pyridinyl)-1-butanone (NNK), the metabolic
capacity of this particular cell line has not been fully characterized
(Ovrevik et al., 2010; Proulx et al., 2005).
Here, BEAS-2B cells were tested and compared to the lung-de-
rived A549 cells broadly used as pulmonary in vitro system but
with no cytochrome P450 expression reported for CYP1A2 and
the CYP2A family, and inducibility documented for CYP1A1/1B1
genes (Hukkanen et al., 2002; Castell et al., 2005). Cells derived
from hepatocarcinomas considered to have a more extensive cyto-
chrome P450 enzyme activity (HepG2 and HepaRG) were used as a
more comprehensive control for our CYP assays (Jennen et al.,
2010). Moreover, the results were contrasted to those reported in
primary human bronchial epithelium culture (Newland et al.,
2011; Courcot et al., 2012). The results of this study are considered
to be useful for in vitro toxicological testing using the cell line
BEAS-2B as cell system. Furthermore, we propose that the outlined
strategy can be incorporated in the characterization of cell systems
used in in vitro testing.2. Materials and methods
2.1. Cell culture
The human bronchial epithelial cell line (BEAS-2B), purchased
from ATCC (United States), was seeded into culture vessels that
had been pre-coated with 0.03 mg/mL PureCol bovine collagen
solution (Nutacon, The Netherlands). Cells were maintained in
Bronchial Epithelial Growth Medium (BEGM) at 37 C and 5%
CO2 in a humidiﬁed incubator. BEGM was prepared by supple-
menting Bronchial Epithelial Basal Medium with growth supple-
ments provided in the manufacturer’s BEGM SingleQuot kit
(Lonza Group Ltd., Belgium) containing: bovine pituitary extract,
hydrocortisone, human epidermal growth factor, epinephrine,
insulin, triiodothyronine, transferrin, gentamicin/amphotericin-B
and retinoic acid.
The human type II alveolar adenocarcinoma-derived (A549) and
hepatocarcinoma-derived (HepG2) cell lines purchased from the
Global Bioresource Centre (ATCC, USA), were maintained in Dul-
becco’s modiﬁed Eagle medium supplemented with fetal bovine
serum (10% v/v), L-glutamine (2 mM), penicillin (50 U/mL) and
streptomycin (50 lg/mL) (complete DMEM) at 37 C and 5% CO2
in a humidiﬁed incubator.
The human hepatocarcinoma-derived cell line (HepaRG) was
purchased as a differentiated conﬂuent monolayer from Biopredic
International (France). After shipment, the cells were maintained
in basal medium supplemented with recovery mix for 24 h fol-
lowed by basal medium supplemented with maintenance/metabo-
lism mix. Media and supplements were provided by the
manufacturer (Biopredic, France).
BEAS-2B, A549 and HepG2 cells were cultured and expanded in-
house. Experiments were performed between passages 3 and 12
only. All cultures were negative for mycoplasma. Additionally,
the cells were authenticated using the short tandem repeat proﬁl-
ing to conﬁrm the nature of the cell cultures (LGC Standards, Uni-
ted Kingdom) (Nims et al., 2010).2.2. Gene expression assay
BEAS-2B, A549 and HepG2 cells were plated in 12-well tissue
culture plates, at 60% conﬂuency. A total of 6 wells per plate were
treated for 48 h with 10 nM of the CYP1A1/1B1 inducer 2,3,7,8-Tet-
rachlorodibenzo-p-dioxin (TCDD). HepaRG cells were not used as
positive control cell line for CYP1A1/1B1, therefore, they were
not pre-induced with TCDD.
After 96 h from seeding, total RNA was isolated from the cells
using the RNeasy mini kit (Quiagen, United Kingdom). The RNA
quantity was measured by using the NanoDrop ND1000 spectro-
photometer (NanoDrop Technologies, USA) and the quality as-
sessed with the Agilent 2100 Bioanalyzer (Agilent, United
Kingdom).
The RNA was converted to cDNA using the high-capacity cDNA
Reverse Transcription Kit (Applied Biosystems, United Kingdom).
qPCR was carried out using custom TaqMan array 96-well plates
and TaqMan Fast Universal Master mix (Applied Biosystem, Uni-
ted Kingdom). Each plate contained two assays with the probes of
1 manufacturing control, 5 endogenous controls and 41 metabo-
lism-related genes from both phase I and phase II (Table 1). qPCR
ampliﬁcation mixtures (20 lL) contained 2 lL of cDNA and 18 lL
of fast master mix and were ampliﬁed using the fast PCR 7500 (Ap-
plied Biosystems, United Kingdom). The cycle conditions com-
prised 2 min at 50 C, 20 s at 95 C, then 40 cycles of 3 s at 95 C
and 30 s at 60 C.
Table 1
Panel of genes classiﬁed by phase of metabolism and function. Standard gene nomenclature taken from (HGNC, 2012).
Controls Phase I
Manufacturing Control Endogenous control Cytochrome P450 Aldo–keto reductases Others
RN18S1 GAPDH CYP1A1 CYP3A4 AKR1B10 EPHX1
HPRT1 CYP1B1 CYP3A5 AKR1C1 CBR1
GUSB CYP1A2 CYP2C9 AKR1C2 DCXR
B2 M CYP2A6 CYP2D6 AKR1C3 AOX1
RPLP0 CYP2A13 CYP2E1 AKR7A3 FMO3
CYP2B6 CYP2F1 HSD11B1
CYP2B7P1 NQO1
Phase II
Glutathione S-transferases UDP-glucuronosyltransferase Others
GSTA1 UGT1A4 SULT1A1
GSTM1 UGT1A6 NAT1
GSTP1 UGT1A7 COMT
GSTT1 UGT1A1
UGT1A8
UGT1A9
UGT1A10
UGT2B7
UGT2B10
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RPLP0, and relative expression levels were calculated using the
DDCt method (Livak and Schmittgen, 2001).
2.3. Cytochrome P450 enzyme activity assays
Range ﬁnder experiments were initially carried out to select
optimal concentrations for substrates, inducer and inhibitors
where maximal activity, induction or inhibition were obtained
without cytotoxicity.
For the enzyme activity proﬁling, phenol free Dulbecco’s Modi-
ﬁed Eagle Medium (DMEM) supplemented with 0.5 mM L-Gluta-
mine was used as a basal experimental medium.
CYP1A1/1B1 activity was measured using the speciﬁc P450-
Glo™ kit (Promega, United Kingdom). The probe used was Luciferin
60 chloroethyl ether (luciferin-CEE) (50 lM) added directly to the
basal medium (0 and 4 h incubation) of 3 wells per condition.
For induced conditions, cultures were pre-incubated for 48 h with
10 nM of TCDD. For inhibited conditions, a-naphthoﬂavone
(10 lM) was added to the basal medium 30 min prior to the probe.
After the incubation, the luminescence was measured using a
LMaxII luminometer (Molecular Devices, United States). HepG2
cells were used as ‘positive control’.
The measurement of CYP2A6/2A13 activity was based on the
methodology described previously (Newland et al., 2011). The
same methodology was adapted, including probes and inhibitors,
for the measurement of CYP1A2 and CYP2E1 activities. A549 cells
were used as ‘negative control’ for CYP2A6/2A13 and CYP1A2, the
status of CYP2E1 activity is unknown in A549. HepaRG cells were
used as a positive control for CYP1A2 and CYP2A6/2A13. HepG2
cells were used as ‘positive control’ for CYP2E1.
For the CYP1A2 activity assay, 7-ethoxyresoruﬁn (20 lM) was
used as a probe and ﬂuvoxamine (100 lM) was used as inhibitor.
The metabolite quantiﬁed was resoruﬁn.
In the case of the CYP2A6/2A13 activity assay, coumarin
(200 lM) was used as a probe and 8-methoxypsoralen (8-MOP)
(100 lM) as inhibitor. The metabolite measured was 7-
hydroxycoumarin.
Finally, the CYP2E1 activity assay used chlorzoxazone (100 lM)
as probe and disulﬁram (20 lM) as inhibitor. 6-hydroxychlorzox-
azone was the metabolite quantiﬁed.
After the probe incubations, 250 lL of basal medium was ad-
justed to pH 5.0 with hydrochloric acid and treated with 2.5 lLof b-glucuronidase from Helix pomatia for 18 h at 37 C while shak-
ing. Once the glucuronidase treatment ﬁnished, 250 lL of metha-
nol and the internal standard 4-methylumbelliferon (5 lM) was
added to the solution. The metabolites where then quantiﬁed using
an UPLC-AB SCIEX/API 4000 Q-Trap mass spectrometer using the
column Phenomenex Kinetex 2.6 lm PFP, 100 Å (Applied Biosys-
tems, United States).
Once all basal medium was removed, cells were lysed using
Mammalian Protein Extraction Reagent (M-PER) lysate buffer
(Thermo Fisher Scientiﬁc Inc., United Kingdom) and protein con-
tent was measured employing the bicinchoninic acid protein assay
(BSA) together with a Multiskan Ascent spectrophotometer (Ther-
mo Fisher Scientiﬁc Inc., United Kingdom).
Lactate dehydrogenase (LDH) release was used as a measure of
cytotoxicity during the enzyme activity assays. The CytoTox-ONE
homogeneous membrane integrity assay (Promega, United King-
dom) was used following manufacture recommendations and ana-
lyzed with a Fluoroskan Ascent ﬂuorometer (Thermo Fisher
Scientiﬁc Inc., United Kingdom). The percentage LDH release is in-
versely proportional to the cell viability which was >85% for all
treatments and timepoints.2.4. Gene expression data analysis
After completion of the qPCR, the threshold cycle (Ct) values
were visually inspected using the fast PCR 7500 software v.2.0.5.
When required, the threshold setting default (0.2) was manually
adjusted to ensure optimal sensitivity was maintained. All
Ct > 36, indicative of the plateau phase of qPCR, were considered
non-expressed genes.
The Ct values were then normalized against the selected endog-
enous control gene to generateDCt values (Ctgene of interest  Ctendog-
enous control gene).2.5. Statistical analysis
All the experiments were repeated three times containing three
replicates per condition and timepoint.
GeneSpring™ GX11.5.1 (Agilent, United Kingdom) was used to
perform the gene expression graphical and statistical analysis.
Principal Component Analysis (PCA) and hierarchical clustering
were selected for graphical representations. For the hierarchical
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linkage was selected for interpretation of the normalized gene
expression data (DCt). One-way ANOVA was used to analyze the
effect of the TCDD induction on the expression of each gene.
The enzyme activity data are represented by the arithmetic
mean of three experiments + standard deviation (SD). Minitab
v.16 was used to perform Student’s t-test. Difference was signiﬁ-
cant when p < 0.05.3. Results
3.1. Gene expression
The ﬁrst stage in the metabolic characterization was to quantify
the mRNAs of a panel of enzyme-encoding genes involved in oxida-
tive (phase I) and conjugative (phase II) metabolism.
The endogenous control gene RPLP0 showed the most stable
expression across the different samples and treatments (data not
shown). Furthermore, RPLP0 has been reported as being highly
conserved across tissues and species (Akamine et al., 2007). There-
fore, RPLP0 was chosen for normalization of data, generating DCt
values (Ctgene of interest  CtRPLP0).
PCA was used to visualize the dataset in a 3D scatter plot graph
shown in Fig. 1. This analysis demonstrated the segregation of cell
lines based on their gene expression proﬁle. The graph shows a
clear separation of the different cell lines (represented by colors)
indicating that the expression proﬁle differs from cell line to cell
line. In addition, only HepG2 cells show a variation between the in-
duced (triangle shaped icon) and non-induced samples (rectangle
shaped icon), while there is no apparent separation of the induced
from the non-induced BEAS-2B and A549 samples. HepaRG cells
were not induced so Fig. 1 only represents the basal gene expres-
sion levels.
The hierarchical cluster shown in Fig. 2 was generated to visu-
alize the gene expression and induction proﬁles of each individual
cell line. This graphical representation contained the expression
value for each individual gene normalized (DCt values); red, blue
and yellow indicate increased (positive DCt), reduced (negative
DCt) and undetectable (DCt close to or 0), respectively. The details
contained in the hierarchical cluster allowed a gene by gene com-
parison between induced and non-induced treatments but also, be-
tween different cell lines. This cluster analysis conﬁrms the
observations made above by PCA. Gene expression proﬁles inFig. 1. 3D scatter plot representing principal component analysis (PCA) of qPCR data. C
HepaRG (grey). Shaped icons represent induction status, triangle (N) represents induc
expression was only measured in non-induced cultures).BEAS-2B and A549 cells do not show a signiﬁcant difference be-
tween induced and non-induced samples. In contrast, the HepG2
proﬁle shows some changes between induced and non-induced
samples. However, there are many genes that are not differentially
expressed. HepaRG cells show a high expression in the majority of
the tested genes.
To allow ﬁne observations between TCDD-induced and non-in-
duced samples, DDCt data representing fold-changes in gene
expression for BEAS-2B, A549 and HepG2 are detailed in Table 2.
As expected, CYP1A1/1B1 were inducible across the three cell
lines. In BEAS-2B cells, CYP1A2 also showed a degree of inducibil-
ity. However, no other gene studied in BEAS-2B cells shows a rele-
vant up- or down-regulation.
3.2. Enzyme activity
The enzymatic activities of four cytochrome P450s enzymes in-
volved in the oxidative metabolism of smoke toxicants were fur-
ther evaluated in BEAS-2B, HepG2, HepaRG, and A549 cells to
complement the gene expression data.
Data represent the rate of metabolite formation in pmol/mg
protein/min, normalized to soluble protein, except for CYP1A1/
1B1 where the metabolite is represented as a measure of lumines-
cence (RLU). Each experiment included data for the cell line in-
tended for characterization (BEAS-2B), A549 and the ‘positive
control’ cell line (Hep-G2 or HepaRG).
Results in Fig. 3A represent CYP1A1/1B1 enzyme activity. In the
absence of TCDD, only background activity was detected for BEAS-
2B (0.0470 RLU/mg/min ±0.0082). In TCDD-induced BEAS-2B, the
activity levels increased 3.7-fold compared to non-induced cells
(0.1740 RLU/mg/min ±0.0317) and were inhibited in the presence
of the CYP1A1/1B1 inhibitor a-naphthoﬂavone. The activity in-
crease in TCDD-treated cells was statistically signiﬁcant with a p
value < 0.0001 and was consistent with the CYP1A1/1B1 mRNA
induction observed in our gene expression data.
HepG2 cells gave a high level of enzyme activity as expected
from the positive control cell line following induction with TCDD.
In contrast, A549 cells produced only background activity both in
the presence and absence of the inducer TCDD (0.0284 and
0.0121 RLU/mg/min respectively).
The results observed for CYP2E1 enzyme activity (Fig. 3B)
showed no statistically signiﬁcant difference in the levels of en-
zyme activity between BEAS-2B or A549 cultures treated in the ab-
sence or presence of inhibitor disulﬁram (p = 0.793 and p = 0.222ell type is represented by color – A549 (red), BEAS-2B (blue), HepG2 (maroon) and
ed cultures and square (j) represents non-induced cultures. (Note: HepaRG gene
-8.9 -0 8.9
Fig. 2. Hierarchical cluster representing the gene expression proﬁles of all four cell lines dependent on treatment (induced or non-induced). (Note: HepaRG gene expression
was only measured in non-induced cultures). Columns represent individual samples and rows represent genes. Red, blue and yellow indicate high signal intensity, low signal
intensity or no signal in normalized gene expression data (DCt), respectively.
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hand, showed a signiﬁcant reduction of enzyme activity in the
presence of inhibitor (p = 0.022).
CYP2A6/2A13 oxidizes coumarin to 7-hydroxycoumarin. The
results presented in Fig. 3C showed no statistically signiﬁcant dif-
ference (p = 0.741) in BEAS-2B CYP2A6/2A13 activity in the pres-
ence and absence of inhibitor 8-MOP. A similar proﬁle was
observed for A549 cells. These results are in agreement with thelack of CYP2A6/2A13mRNA expression (Ct > 36). HepaRG cells (po-
sitive control cell line) showed a reduction in enzyme activity in
the presence of inhibitor (p < 0.0001).
Fig. 3D represents the enzyme activity levels measured for
CYP1A2. The results showed that the levels of activity detected in
BEAS-2B cells were equivalent to those observed when the CYP1A2
inhibitor ﬂuvoxamine was present in the cultures. These results
concurred with the results obtained for CYP1A2 gene expression
Table 2
Gene expression data represented as fold change comparing TCDD-induced with non-
induced cells. In red: genes with at least 2-fold increase in gene expression after
induction (up-regulated). In blue: genes with at least 2-fold decrease in gene
expression after induction (down-regulated).
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CYP1A2 gene in BEAS-2B cells based on a Ct > 36. HepaRG cells (po-
sitive control cell line) showed a reduction in enzyme activity (1.6-
fold) in the presence of inhibitor, however, this reduction was not
statistically signiﬁcant (p = 0.127).4. Discussion
The lung-derived cell line BEAS-2B has been identiﬁed as a cell
line of interest in the in vitro toxicological testing of inhaled toxi-
cants (Veljkovic et al., 2011; Ansteinsson et al., 2011). However,
to date the metabolic capabilities of this cell line have not been
thoroughly investigated. In this study, we employed high through-
put technology to provide a rapid screening for gene expression
and inducibility for a panel of 41 metabolism-related genes, pro-
ducing a proﬁle of gene expression and gene inducibility. Then,
four key CYP enzymes involved in the bioactivation of some smoke
pro-toxicants were selected for functional enzyme activity assay.
The data obtained from both analysis would conﬁrm if enzyme
activity was consistent with gene expression. The scientiﬁc ap-
proach used in this study is a working example of our proposedstrategy for the metabolic characterization of cell systems used
in the context of in vitro toxicology testing.
Our gene expression results show that non-induced BEAS-2B
cells have high and moderate mRNA expression for, GSTM1 and
SULT1A1 respectively, both related to conjugative reactions which
mainly act as detoxiﬁcation mechanisms (Castell et al., 2005). As
expected, when cultures were pre-induced with TCDD, CYP1A1,
CYP1B1 and CYP1A2 genes showed an up-regulation of 25-fold,
6-fold and 4-fold respectively compared with non-induced cul-
tures. The up-regulation of CYP1A1 and CYP1B1 genes after pre-
incubation with TCDD has also been reported in normal human
primary bronchial epithelium (NHBE) cells (Newland et al.,
2011). Surprisingly, in a recent publication Courcot and colleagues
report high levels of CYP1B1 gene expression in non-induced cul-
tures of BEAS-2B cells and high levels of CYP1A1/1B1 gene expres-
sion in non-induced cultures of human primary bronchial
epithelium cells (HBEC), among other lung cell systems (Courcot
et al., 2012). This contrasts with our gene expression results and
other published results (Newland et al., 2011; Castell et al.,
2005). It is possible that the high levels of CYP1A1 and CYP1B1 re-
ported in HBEC by Courcot and colleagues could be as a result of
the smoking habit of the donor; cigarette smoke is known to acti-
vate these enzymes in the lung (Nishikawa et al., 2004; Anttila
et al., 2011). However, this information is not disclosed in their
methodology. In order to conﬁrm the relevance of the gene expres-
sion, activity assessment is generally recommended as a follow up
experiment.
The gene expression results we obtained were compared with
the enzyme activity data obtained for the tested CYPs (CYP1A1/
1B1, CYP1A2, CYP2A6/2A13 and CYP2E1). When BEAS-2B cells
were pre-incubated with TCDD, CYP1A1/1B1 activity showed a sta-
tistically signiﬁcant increase compared to non-treated cultures
(Fig. 3A). This concurs with the gene up-regulation described ear-
lier. TCDD-induced BEAS-2B cells showed an activity of 0.2 RLU/
mg/min while HBEC cultures have been reported to show an en-
zyme activity level between 4.3 and 7.3 RLU/mg protein/min
(Newland et al., 2011). No activity was observed in BEAS-2B cells
for the other three CYPs analyzed (CYP2E1, CYP2A6/2A13 and
CYP1A2) which conﬁrms the ﬁndings from our gene expression
analysis. Previous studies have also reported no detectable CYP1A2
activity in BEAS-2B cells and lung microsomes (Van Vleet et al.,
2002; Shimada et al., 1992), however, CYP1A2 activity could be in-
duced by environmental factors and speciﬁc CYP1A2 gene poly-
morphisms increasing lung cancer risk as recently reviewed
(Pavanello et al., 2012). The activity related to CYP2A and CYP2E1
has not been previously reported in BEAS-2B cells, but has been de-
tected in human lung (Hukkanen et al., 2002). Newland et al. also
reported that HBEC cultures from three different donors showed a
CYP2A6/2A13 activity between 0.15 and 1.33 pmol/mg/min (New-
land et al., 2011) a similar study by Runge and colleagues showed
that CYP2E1 activity in HBEC (0.6 pmol/mg/min), however sub-
stantial inter-individual variability was reported as only two out
of the four donors showed CYP2E1 activity (Runge et al., 2001).
Overall, the relative enzyme activity level in BEAS-2B cells ap-
pears limited compared with normal tissue. For instance, immu-
nobloting of human lung microsomes have been used to detect
CYP1A1, 1B1, 2A6, 2B6, 2C9, 2D6, 2E1, 2F1 and 3A4/5 in normal air-
way tissue (Hukkanen et al., 2002; Bernauer et al., 2006). In HBEC,
these CYPs have been reported to show both gene expression and
enzyme activity, however, high interindividual variability between
different donors was also noted (Runge et al., 2001; Newland et al.,
2011; Anttila et al., 2011; Castell et al., 2005). The lack of gene
expression for the majority of metabolizing enzyme-encoding
genes tested, with or without induction by TCDD, and the lack of
activity for three out of the four selected P450 enzymes indicates
that BEAS-2B cells might not be suitable to study the toxicity of
Fig. 3. Enzyme activity represented by metabolite formation. (A) Luciferin formation measured in BEAS-2B (a), A549 (c) and Hep-G2 (b) with and without induction with
TCDD in the presence and absence of a speciﬁc inhibitor (a-naphthoﬂavone). Luciferin rate of formation is indicative of CYP1A1/1B1 activity when luciferin-CEE was used as a
substrate. (B) 6-Hydroxychlorzoxazone formation measured in BEAS-2B (a), A549 (c) and Hep-G2 (b) in the presence and absence of a speciﬁc inhibitor (disulﬁram). 6-
Hydroxychlorzoxazone rate of formation is indicative of CYP2E1 activity when chlorzoxazone was used as a substrate. (C) 7-Hydroxycoumarin formation measured in BEAS-
2B (a), A549 (c) and HepaRG (d) in the presence and absence of a speciﬁc inhibitor (8-MOP). 7-hydroxycoumarin rate of formation is indicative of CYP2A6/2A13 activity when
coumarin was used as a substrate. (D) Resoruﬁn formation measured in BEAS-2B (a), A549 (c) and HepaRG (d) in the presence and absence of a speciﬁc inhibitor
(ﬂuvoxamine). Resoruﬁn ratio of formation is indicative of CYP1A2 activity when 7-ethoxyresoruﬁn was used as a substrate. CYP activities are expressed as the mean + SD of
three independent experiments with triplicate samples. The asterisk () indicates a p < 0.001.
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bolic activation (S9 fractions, microsomes, co-cultures or in vitro li-
ver-like cell lines amongst others) (Brandon et al., 2003).
Alternatively to an external source of metabolic activation, Macé
and colleagues developed a series of cell lines, derived from
BEAS-2B cells, expressing one single human cytochrome P450
cDNA, CYP1A2, 2A6, 2B6, 2C9, 2D6, 2E1, 2F1, 3A4 and 3A5 (Mace
et al., 1997a,b). These cell lines have been mainly used for the tox-
icological assessment of single compounds (Mace et al., 1994; Van
Vleet et al., 2002; Nichols et al., 2003). Although useful for the tox-
icity evaluation of single compounds, genetically engineered cell
lines have toxicity testing limitations with complex mixtures and
compounds with unknown metabolic pathway. The complex mix-
ture could contain various pro-toxicants bioactivated by multiple
CYPs. Nevertheless, pro-toxicants which are metabolised by
CYP1A1/1B1 enzymes such as PAHs could be bioactivated in pre-
induced BEAS-2B cultures. In this study CYP1A1/1B1 gene expres-
sion and enzyme activity were induced using TCDD, however,
other xenobiotics such as B[a]P have been used previously to in-
duce these isoforms (Nebert et al., 1993; Tsuji and Walle, 2006).
It is important to consider that the BEAS-2B cell line has a wider
application for biological endpoint assessment such as DNA dam-
age and repair mechanisms in vitro. The non-cancerous phenotype
and wild-type p53 status of the BEAS-2B cell line makes them an
ideal cell system in cell transformation research (Reddel et al.,
1988; Petitjean et al., 2007; IARC-TP53, 2013). Moreover, the‘‘oncogenic stress’’ exhibited by pre-malignant and cancer tissues
could affect the measure of certain biomarkers of DNA damage
such as the cH2AX (Svetlova et al., 2010). The BEAS-2B cell line
has also been selected as a cell system in the study of nanomateri-
als cellular transport and intracellular response (Gilbert et al.,
2012; Ekstrand-Hammarstroem et al., 2012).
During this study a number of well-characterized cell lines were
used in parallel with the same treatment conditions. The A549 cell
line was selected as a lung carcinoma-derived cell system for com-
parison purpose while the HepG2 and HepaRG cell lines were used
as ‘positive control’ with a more extensive cytochrome P450 en-
zyme activity. A549 cells showed a small number of up-regulated
genes in basal cultures such as AKR1B10 and AKR1C2 known to
be associated with the cell line’s tumorigenic origin (Quinn et al.,
2008). As expected, in pre-induced cultures CYP1A1 and CYP1B1
genes were up-regulated (260-fold and 14-fold increase respec-
tively). Interestingly, in our study the up-regulation of these genes
was not translated into enzyme activity. The lack of CYP1A1/1B1
enzyme activity has been observed previously (Newland et al.,
2011). With respect to the results obtained for HepG2 and HepaRG
cells, we observed that HepaRG express more genes involved in
phase I and phase II metabolism than HepG2. Our results concur
with data published previously (Gerets et al., 2012; Jennen et al.,
2010).
Our data on BEAS-2B have shown a different proﬁle to the data
published recently by Courcot et al. They recommended BEAS-2B
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in the lung, based on gene expression similarities between these
cells and primary cultured cells (Courcot et al., 2012). Although,
our functional experiments include a subset of metabolic enzymes,
our results suggest that BEAS-2B cells do not have signiﬁcant phase
I metabolism capabilities. The different results could be explained
by variations in the culture conditions and cell origin. These proto-
col variations have been reported as causes of differences in phase I
and phase II activities (Hewitt and Hewitt, 2004). Nevertheless,
while qPCR is a sensitive method to measure gene expression,
not all mRNAs are translated into active proteins. There are multi-
ple processes that could interfere with the translation and activa-
tion of proteins from mRNA one example is the emerging ﬁeld of
microRNA research which has shown the ability to modify the reg-
ulation of both gene expression and translation (Lee and Vasud-
evan, 2013). Thus, mRNA level is not always correlated with
protein or activity. For instance, Halladay and colleagues studied
the induction of various hepatic cytochrome P450 at the mRNA,
protein and activity level from different donors. For CYP1A2, the
inducer rifampicin did not increased mRNA and protein levels
(1.00 and 1.03-fold induction respectively), however, the activity
was induced by an average of 2.55-fold (one donor’s activity reach-
ing above 4-fold induction). On the contrary, CYP3A4/5 inducer
ritonavir (5 lM) increased mRNA expression by 2.5-fold but pro-
tein and activity levels were not induced (<0.3-fold induction)
(Halladay et al., 2012). In our study, we observed that the HepG2
cell line showed enzyme activity for both CYP1A1/1B1 and CYP2E1
(Fig. 3A and B) but a low mRNA expression was detected in un-in-
duced HepG2 cultures (Fig. 2). The lack of correlation between
activity and mRNA could be caused by post-transcriptional factors
and is also a function of the protein stability. Also, it is worth not-
ing that the mRNA expression of both CYP1A1/1B1 and CYP2E1
was upregulated in induced HepG2 cultures, the substrates used
during the enzyme activity assays could have had an inducibility
effect. For these reasons, key enzymatic activities should be in-
cluded in any metabolic characterization to conﬁrm the gene
expression results prior the use of the cell line for further in vitro
toxicological testing.
In summary, we would like to outline an experimental strategy
that beneﬁts from the high throughput of qPCR but includes key
functional assays (i.e. enzymatic activity).
i. Deﬁne an experimental design considering the nature of the
test article, route of exposure and metabolic pathways. In
our study, the experimental design was orientated towards
toxicological studies on cigarette smoke toxicants.
ii. Obtain the cell systems from an established supplier such as
the European Collection of Cell Cultures (ECACC) to avoid the
propagation of misidentiﬁed cultures (Lacroix, 2008). Fur-
thermore, whenever the cell line is expanded in-house, sim-
ple authentication methods will conﬁrm the authenticity of
the cells (Nims et al., 2010).
iii. Select a panel of pathway-relevant metabolism genes to
carry out expression analysis.
iv. Assess corresponding enzyme activity.
The metabolic characterization of the cell line BEAS-2B carried
out in this study will support future experimental designs, taking
into account the cell system limitations. Moreover, we propose
that this strategy can be applied to unravel the metabolic capabil-
ities of other cell systems considered for in vitro toxicology testing.Conﬂict of interest
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